Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Lexagene Holdings Inc LXXGQ

Healthcare Medical Devices
Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in... see more

GREY:LXXGQ - Post Discussion

Lexagene Holdings Inc > Lexagene has a large competitive advantage & will be bought
View:
Post by Notmypres on Dec 13, 2021 6:15pm

Lexagene has a large competitive advantage & will be bought

I like the technology and trust the leadership. I suspect, with no direct evidence, that the surprising sluggishness in sales and refinancing is not due to the market, so much as it is with a pending buyout. GLTA
Comment by ARIMA11 on Dec 16, 2021 5:36pm
Well that certainly would be a fortunate outcome but the current valuation is not reflective of it. The 510k clearance and CLIA-waiver with the FDA must definitely impact near terms sales as many clients might be waiting for these to sign in. Either way the key will be versioning for them.      
Lexagene Holdings Inc